Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2007-10-29 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming announces completion of randomized treatments in North American clinical trial with Rhucin
Regulatory Filings Classification · 92% confidence The document is a press release announcing the completion of randomized treatments in a North American clinical trial for the drug Rhucin®. It details the trial status, mentions positive open-label results, and outlines future filing plans (EMEA opinion, FDA BLA filing). This type of announcement, focusing on clinical trial progress and immediate operational updates rather than comprehensive financial results (like a 10-K or IR) or management changes (MANG), typically falls under a general regulatory announcement or an earnings-related update. Since it is not a formal Earnings Release (ER) which focuses on financial figures, nor a Call Transcript (CT), and it is a specific operational update, it best fits the general 'Regulatory Filings' (RNS) category as a significant corporate development announcement, or potentially an 'Earnings Release' (ER) if the context implies it's tied to a reporting period, but the focus here is purely clinical/operational progress. Given the options, RNS serves as the best catch-all for significant, non-financial, non-governance corporate news releases. The length (5685 chars) is substantial enough to be a standalone announcement, not just a brief RPA.
2007-10-29 English
Pharming announces third quarter 2007 results
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report for Pharming Group NV for the period ending September 30, 2007. It contains detailed financial highlights, management commentary on business operations, and consolidated financial statements (balance sheet and income statement). It is not merely an announcement of a report, but the report itself, containing substantive financial data for the nine-month period. Therefore, it is classified as an Interim/Quarterly Report. 9M 2007
2007-10-19 English
Pharming announces third quarter 2007 results
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report for Pharming Group NV for the period ended September 30, 2007. It contains a narrative summary of financial and operational performance, followed by consolidated balance sheets and income statements. Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2007
2007-10-19 English
Pharming raises 70 million euro through the issue of convertible bonds
Capital/Financing Update Classification · 99% confidence The document is a press release dated October 19, 2007, announcing that Pharming Group N.V. has raised €70 million through the issue of convertible bonds and is restructuring a financing agreement with Paul Capital Healthcare. The core subject matter is a significant financing activity (issuing bonds and repaying debt). This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about capital structure changes, CAP is the most appropriate classification over the general 'RNS'. The document length (5096 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2007-10-19 English
Pharming raises 70 million euro through the issue of convertible bonds
Capital/Financing Update Classification · 99% confidence The document announces two major financial events: the issuance of a €70 million convertible bond and the restructuring of a financial agreement with Paul Capital Healthcare. The core subject is fundraising, debt restructuring, and capital structure changes. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is a press release, the content is substantive financial news rather than just an announcement of a report's publication (RPA/RNS).
2007-10-19 English
Pharming receives Orphan Drug designation for recombinant fibrinogen from FDA
Regulatory Filings Classification · 95% confidence The document is a press release dated October 11, 2007, announcing that Pharming Group N.V. received Orphan Drug designation from the FDA for recombinant human fibrinogen (rhFIB). It details the medical context, market size, and the company's development strategy. This type of announcement, focusing on a specific regulatory milestone (Orphan Drug Designation) and providing key business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal announcement of a significant event rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), and it doesn't fit the specific categories like Director's Dealing (DIRS) or Capital Change (CAP), it aligns best with an Earnings Release (ER) which often includes material non-financial news, or RNS as a general regulatory announcement. Given the structure and content (announcement of a key development), ER is a strong candidate, but RNS is the safest fallback for non-standard, material announcements. However, many companies issue these types of press releases alongside or instead of formal quarterly reports to disseminate material news. Since it is a formal announcement of a regulatory event and business update, and not a full financial report, I will classify it as an Earnings Release (ER) as these often contain material news beyond just the numbers, or RNS. Given the options, and that it is a press release announcing a specific regulatory achievement, ER is often used for such material news releases, but RNS is the catch-all for regulatory announcements. I will lean towards RNS as it is a specific regulatory announcement that isn't a full financial report or a call transcript.
2007-10-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.